The Trump administration’s direct negotiations with pharmaceutical giants just delivered an 86% price cut on a blockbuster arthritis drug, bypassing the traditional insurance system that has left millions of uninsured Americans paying sky-high list prices.
Story Highlights
- AbbVie and Genentech become the 10th and 11th pharmaceutical companies to join TrumpRx, expanding the portal to 61 discounted drugs
- Humira drops from $6,900 to $950 for uninsured patients—an 86% discount on one of America’s most prescribed medications
- Genentech’s flu treatment Xofluza falls to $50 from $168, benefiting those paying out-of-pocket
- Companies secured tariff exemptions and policy incentives in exchange for price cuts and U.S. manufacturing commitments
Trump Administration Expands Direct Drug Portal
The White House announced April 6, 2026, that AbbVie and Genentech will launch discounted medications on the government-run TrumpRx.gov portal, with availability starting as soon as April 7.
The expansion brings the total number of participating pharmaceutical companies to eleven, offering uninsured Americans access to 61 prescription drugs at prices significantly below standard retail costs.
This marks a substantial growth since the portal’s February 2026 debut with 40 medications from nine companies, including AstraZeneca, Eli Lilly, Novo Nordisk, and Pfizer.
The initiative targets the estimated millions of Americans without insurance coverage who face the full brunt of list prices that remain the highest in the developed world.
CBS News Exclusive: Drug-making giants Abbvie and Genentech will start selling medications at a discount soon on TrumpRx. https://t.co/vo4KCd2bkX
— CBS News (@CBSNews) April 6, 2026
Steep Discounts on Blockbuster Medications
AbbVie’s Humira, a leading treatment for rheumatoid arthritis, Crohn’s disease, and ulcerative colitis, will sell for $950 through TrumpRx compared to up to $6,900 that uninsured patients previously paid—representing an 86% reduction.
Genentech’s Xofluza, an influenza prevention and treatment medication, drops to $50 from $168. These discounts apply exclusively to uninsured individuals or those paying out of pocket without insurance reimbursement.
Patients with insurance coverage already receive lower negotiated rates through their plans and will not see changes.
The administration frames this as relief for a vulnerable population caught in a healthcare system where insured and uninsured Americans pay vastly different amounts for identical medications.
Behind the Deals: Tariffs and Manufacturing
The pharmaceutical companies secured significant policy benefits in exchange for joining TrumpRx. Genentech’s December 2025 agreement exempted its drug portfolio from tariffs, reduced Medicaid pricing obligations, and tied to a $50 billion U.S. investment commitment including a new North Carolina manufacturing facility.
AbbVie’s January 2026 deal similarly improved Medicaid pricing terms and enhanced direct-to-patient affordability while aligning with administration goals for domestic production.
This approach reflects the government’s strategy of leveraging regulatory power and tariff policy to extract pricing concessions without imposing direct price controls.
Critics on both sides of the political spectrum might see this as either smart negotiation or corporate favoritism, depending on their perspective on government intervention in markets.
Questions About Broader Healthcare Access
While the discounts provide tangible relief for uninsured patients, they underscore a fundamental problem: the pharmaceutical pricing system remains opaque and wildly inconsistent. Insured patients already pay far less than the list prices TrumpRx is cutting, raising questions about why such disparities existed in the first place.
The portal bypasses traditional insurance and pharmacy benefit managers, suggesting those intermediaries may contribute to inflated costs.
Simultaneously, pharmaceutical companies gain tariff exemptions and favorable regulatory treatment, prompting concerns among those who believe government deals with corporations often benefit the powerful at the expense of systemic reform.
Whether this represents a genuine victory for everyday Americans or a short-term fix that leaves deeper structural issues unaddressed will likely fuel ongoing debate across the political spectrum.
Expansion Signals Growing Momentum
The addition of AbbVie and Genentech, alongside Amgen’s simultaneous expansion of offerings such as Enbrel and Otezla, signals growing pharmaceutical industry participation in the Trump administration’s direct-to-consumer model.
With eleven companies now involved and more than 60 drugs available, the portal has exceeded initial projections from its February launch.
The administration’s July 2025 letter outlining priorities for drug pricing, innovation rewards, and U.S. manufacturing set the framework for these deals, and momentum suggests additional companies may join to secure similar policy advantages.
For frustrated Americans who feel the healthcare system prioritizes profits over patients, this expansion offers a concrete example of government action—though whether it represents meaningful reform or political theater depends on one’s trust in both the administration and corporate pharmaceutical motives.
Sources:
Two more major pharmaceutical companies to launch products through TrumpRx – Just the News
Two more pharmaceutical companies, Abbvie and Genentech, to officially launch on TrumpRx – CBS News
Genentech Announces Agreement with US Government – Genentech Press Release
